日本の製薬業<br>The Japanese Pharmaceutical Industry : The New Drug Lag and the Failure of Industrial Policy

個数：

日本の製薬業
The Japanese Pharmaceutical Industry : The New Drug Lag and the Failure of Industrial Policy

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    【重要ご説明事項】
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版／ページ数 232 p.
  • 言語 ENG
  • 商品コード 9781840645804
  • DDC分類 338.4761510952

基本説明

This book provides a detailed examination of how Japan has socially constructed its pharmaceutical industry, the economic and political bases of this construction and the consequences for corporate innovation and performance.

Full Description

Japan has succeeded in many industries through its renowned production system. Competitive advantage, however, in the new economy is shifting from production to demand-based capabilities. One such new industry is pharmaceuticals, where Japan has been a resounding failure, both from public policy and corporate strategy perspectives. This book provides a detailed examination of how Japan has socially constructed its pharmaceutical industry, the economic and political bases of this construction and the consequences for corporate innovation and performance.Perhaps the starkest indication of this failure of Japanese public policy is the emergence of a new drug lag in that nation. Almost 90 percent of recent important new drugs are unavailable in Japan, despite their widespread diffusion throughout the rest of the world. Analysis of this drug lag confirms that it is not due to government discrimination against Western firms, but rather is only one of many consequences of failed Japanese industrial policies.

The author presents an analysis of the nature, causes and consequences of the new drug lag in Japan. He contrasts the problem with the one experienced in the US and looks at the powerful role played by domestic politics in shaping the pharmaceutical industry. The last chapters look at the various remedies available. Academics, experts in government and industry, researchers and students of industrial policy, economics, public health and trade policy will find the examination of this important industry both informative and enlightening.

Contents

Contents: Introduction 1. Nature of the New Drug Lag 2. Industrial Policy and Domestic Ecosystems 3. The Domestic Japanese Ecosystem for Pharmaceuticals 4. Pathologies of the Japanese Domestic Ecosystem 5. Evidence: Declining Prices and Life Cycle Sales in Japan 6. Evidence: Declining Registrations in Japan 7. Evidence: Declining Launches in Japan 8. Evidence: Inflated Domestic Market Share in Japan 9. Challenges to the Dual State in Japan 10. Trade Law and Remedies for Market Exclusion References Index